Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer

Tumori

Volumn 100, Issue 4, 2014, Pages 370-376

  Varol, Umut ^a   Yildiz, Ibrahim ^a   Salman, Tarik ^a   Karabulut, Bulent ^b   Uslu, Ruchan ^b  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Bevacizumab; Biomarker; Colorectal cancer; Efficacy; Metastasis

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBONATE DEHYDRATASE IX; CARCINOEMBRYONIC ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTATE DEHYDROGENASE; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D; ANGIOGENESIS INHIBITOR; B RAF KINASE; BRAF PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRANSCRIPTOME; VEGFA PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; CANCER SURVIVAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; EPHB4 GENE; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; ONCOGENE B RAF; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; CHEMICALLY INDUCED; COLORECTAL NEOPLASMS; COMPLICATION; DRUG ERUPTIONS; GENETICS; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; OBESITY; ONCOGENE RAS; PATHOLOGY; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLORECTAL NEOPLASMS; DRUG ERUPTIONS; ENDOTHELIAL PROGENITOR CELLS; GENES, RAS; HUMANS; HYPERTENSION; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; OBESITY; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; TRANSCRIPTOME; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908153983     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.1700/1636.17888     Document Type: Review

References (75)

1. Borgström P, Hillan KJ, Sriramarao P, Ferrara N: Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res, 56: 4032-4039, 1996.
2. Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N: Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest, 95: 1789-1797, 1995.
3. Strickler JH, Hurwitz HI: Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist, 17: 513-524, 2012.
4. Chibaudel B, Tournigand C, André T, de Gramont A: Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol, 4: 75-89, 2012.
5. Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S: Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther, 5: 199-211, 2012.
6. Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W, Gao S: Safety of bevacizumab in treating metastatic colorectal cancer: A systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig, 33: 779-788, 2013.
7. Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D: Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol, 20: 1842-1847, 2009.
8. Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A: Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. Oncologist, 14: 862-870, 2009.
9. Ranpura V, Pulipati B, Chu D, Zhu X, Wu S: Increased risk of high-grade HTN with bevacizumab in cancer patients: A meta-analysis. Am J Hypertens, 23: 460-468, 2010.
10. Horinouchi Y, Sakurada T, Nakamura T, Tajima S, Nishisako H, Abe S, Teraoka K, Kujime T, Kawazoe K, Minakuchi K: Hypertension as a predictive factor of effect of bevacizumab in treatment of colorectal cancer. Yakugaku Zasshi, 131: 1251-1257, 2011.
11. Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A: Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol, 30: 327, 2013.
12. Österlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P: Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer, 104: 599-604, 2011.
13. De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S: Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol, 68: 1207-1213, 2011.
14. Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S: Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol, 20: 227-230, 2009.
15. Yamamura K, Ishigure K: Analysis of hypertension in advanced, recurrent colorectal cancer patients treated with firstline bevacizumab. Gan To Kagaku Ryoho, 38: 85-88, 2011.
16. Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O: Analysis of early hypertension and clinical outcome with bevacizumab: Results from seven phase III studies. Oncologist, 2013; 18: 273-280, 2013.
17. Saif MW, Longo WL, Israel G: Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer, 7: 144-148, 2008.
18. Gotlib V, Khaled S, Lapko I, Mar N, Saif MW: Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs, 17: 1227-1229, 2006.
19. Iwasa S, Nakajima TE, Nagashima K, Honma Y, Kato K, Hamaguchi T, Yamada Y, Shimada Y: Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer. Anticancer Res, 33: 309-316, 2013.
20. Moghaddam AA, Woodward M, Huxley R: Obesity and risk of colorectal cancer: A meta-analysis of 31 studies with 70, 000 events. Cancer Epidemiol Biomarkers Prev, 16: 2533-2547, 2007.
21. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Saito Y: Elevated serum vascular endothelial growth factor is associated with visceral fat accumulation in human obese subjects. Diabetologia, 46: 1483-1488, 2003.
22. Sridhar SS, Goodwin PJ: Insulin-insulin-like growth factor axis and colon cancer. J Clin Oncol, 27: 165-167, 2009.
23. Cao Y: Angiogenesis modulates adipogenesis and obesity. J Clin Invest, 117: 2362-2368, 2007.
24. Guiu B, Petit JM, Bonnetain F, Ladoire S, Guiu S, Cercueil JP, Krausé D, Hillon P, Borg C, Chauffert B, Ghiringhelli F: Visceral fat area is an independent predictive biomarker of outcome after first-line bevacizumab-based treatment in metastatic colorectal cancer. Gut, 59: 341-347, 2010.
25. Aykan FN, Yildiz I, Sen F, Kilic L, Keskin S, Ciftci R, Karabulut S, Sakar B, Disci R: Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy. Med Oncol, 30: 679, 2013.
26. Scartozzi M, Giampieri R, Maccaroni E, Del Prete M, Faloppi L, Bianconi M, Galizia E, Loretelli C, Belvederesi L, Bittoni A, Cascinu S: Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumabbased therapy in metastatic colorectal cancer patients. Br J Cancer, 106: 799-804, 2012.
27. Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ: Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer, 9: 246, 2009.
28. Formica V, Massara MC, Portarena I, Fiaschetti V, Grenga I, Del Vecchio Blanco G, Sileri P, Tosetto L, Skoulidis F, Pallone F, Roselli M: Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomark, 5: 167-175, 2009.
29. de Andrade DP, Lima JP, Lima AD, Sasse AD, dos Santos LV: Bevacizumab in metastatic colorectal cancer and carcinoembryonic antigen kinetics: Case report and review of literature. Anticancer Drugs, 22: 15-17, 2011.
30. Suenaga M, Matsusaka S, Ueno M, Yamamoto N, Shinozaki E, Mizunuma N, Yamaguchi T, Hatake K: Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surg Today, 41: 1067-1074, 2011.
31. Guijarro-Muñoz I, Sánchez A, Martínez-Martínez E, García JM, Salas C, Provencio M, Alvarez-Vallina L, Sanz L: Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol, 30: 572, 2013.
32. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ: Pharmacogenetic pro-filing of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumabbased chemotherapy. Pharmacogenomics J, 13: 173-180, 2013.
33. Budai B, Komlósi V, Adleff V, Pap E, Réti A, Nagy T, Kralovánszky J, Láng I, Hitre E: Impact of SHMT1 polymorphism on the clinical outcome of patients with metastatic colorectal cancer treated with first-line FOLFIRI+bevacizumab. Pharmacogenet Genomics, 22: 69-72, 2012.
34. Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'Aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, Tonini G: Dicer and Drosha expression and response to bevacizumab-based therapy in advanced colorectal cancer patients. Eur J Cancer, 49: 1501-1508, 2013.
35. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Ikeuchi H: Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. Dis Colon Rectum, 54: 1026-1035, 2011.
36. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ, Koeppen H: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol, 24: 217-227, 2006.
37. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F, Roselli M: Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab. Int J Colorectal Dis, 26: 143-151, 2011.
38. Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M, Chopitea A, Bandres E, Garcia-Foncillas J: Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer, 103: 1529-1535, 2010.
39. Hansen TF, Christensen RD, Andersen RF, Garm Spindler KL, Johnsson A, Jakobsen A: The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: Results from the Nordic ACT trial. Int J Colorectal Dis, 27: 715-720, 2012.
40. Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ: Association between VEGF splice isoforms and progressionfree survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res, 18: 6384-6391, 2012.
41. Aoyagi Y, Iinuma H, Horiuchi A, Shimada R, Watanabe T: Association of plasma VEGF-A, soluble VEGFR-1 and VEGFR-2 levels and clinical response and survival in advanced colorectal cancer patients receiving bevacizumab with modified FOLFOX6. Oncol Lett, 1: 253-259, 2010.
42. Koutras AK, Antonacopoulou AG, Eleftheraki AG, Dimitrakopoulos FI, Koumarianou A, Varthalitis I, Fostira F, Sgouros J, Briasoulis E, Bournakis E, Bafaloukos D, Bompolaki I, Galani E, Kalogeras KT, Pectasides D, Fountzilas G, Kalofonos HP: Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab. Pharmacogenomics J, 12: 468-475, 2012.
43. Weickhardt AJ, Williams D, Lee C, Simes J, Murone C, Wilson K, Cummins M, Asadi K, Price TJ, Mariadason J, Tebbutt NC: Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study. J Clin Oncol, 29: 3531, 2011.
44. Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI: Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB80303 (Alliance). Clin Cancer Res, 19: 6957-6566, 2013.
45. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ, Chen DS: Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res, 19: 929-937, 2013.
46. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ: Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol, 31: 1219-1230, 2013.
47. Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ: Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One, 8: 66774, 2013.
48. Loupakis F, Ruzzo A, Salvatore L, Cremolini C, Masi G, Frumento P, Schirripa M, Catalano V, Galluccio N, Canestrari E, Vincenzi B, Santini D, Bencardino K, Ricci V, Manzoni M, Danova M, Tonini G, Magnani M, Falcone A, Graziano F: Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 11: 247, 2011.
49. Loupakis F, Cremolini C, Fioravanti A, Orlandi P, Salvatore L, Masi G, Di Desidero T, Canu B, Schirripa M, Frumento P, Di Paolo A, Danesi R, Falcone A, Bocci G: Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer, 104: 1262-1269, 2011.
50. Ince WL, Jubb AM, Holden SN, Holmgren EB, Tobin P, Sridhar M, Hurwitz HI, Kabbinavar F, Novotny WF, Hillan KJ, Koeppen H: Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst, 97: 981-989, 2005.
51. Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O: The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist, 14: 22-28, 2009.
52. Imaizumi H, Ishibashi K, Okada N, Tajima Y, Amano K, Hatano S, Kuwabara K, Sobajima J, Ishiguro T, Ohsawa T, Kumamoto K, Kumagai Y, Haga N, Ishida H: Clinical outcomes in refractory colorectal cancer patients with wildtype K-ras treated with bevacizumab and oxaliplatinbased chemotherapy as a first-line treatment. Gan To Kagaku Ryoho, 39: 2185-2188, 2012.
53. Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC: Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. J Clin Oncol, 29: 2675-2682, 2011.
54. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S: KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: A pooled analysis of 12 published trials. Med Oncol, 30: 650, 2013.
55. Price TJ, Hardingham JE, Lee CK, Townsend AR, Wrin JW, Wilson K, Weickhardt A, Simes RJ, Murone C, Tebbutt NC: Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Med, 2: 277-285, 2013.
56. Kara O, Duman BB, Kara B, Erdogan S, Parsak CK, Sakman G: Analysis of PTEN, VEGF, HER2 and P53 status in determining colorectal cancer benefit from bevacizumab therapy. Asian Pac J Cancer Prev, 13: 6397-6401, 2012.
57. Janku F, Wheler JJ, Hong DS, Kurzrock R: Bevacizumabbased treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol, 8: 183-188, 2013.
58. Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE: Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol, 15: 139-145, 2004.
59. Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, Bencardino K, Rovati B, Tinelli C, Falcone A, Villa E, Danova M: Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol, 21: 2382-2389, 2010.
60. Simkens LH, Tol J, Terstappen LW, Teerenstra S, Punt CJ, Nagtegaal ID: The predictive and prognostic value of circulating endothelial cells in advanced colorectal cancer patients receiving first-line chemotherapy and bevacizumab. Ann Oncol, 21: 2447-2448, 2010.
61. Sastre J, Maestro ML, Gómez-España A, Rivera F, Valladares M, Massuti B, Benavides M, Gallén M, Marcuello E, Abad A, Arrivi A, Fernández-Martos C, González E, Tabernero JM, Vidaurreta M, Aranda E, Díaz-Rubio E: Circulating tumour cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumours study. Oncologist, 17: 947-955, 2012.
62. Matsusaka S, Suenaga M, Mishima Y, Takagi K, Terui Y, Mizunuma N, Hatake K: Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer. Cancer Chemother Pharmacol, 68: 763-768, 2011.
63. Malka D, Boige V, Jacques N, Vimond N, Adenis A, Boucher E, Pierga JY, Conroy T, Chauffert B, François E, Guichard P, Galais MP, Cvitkovic F, Ducreux M, Farace F: Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. Ann Oncol, 23: 919-927, 2012.
64. Manzoni M, Mariucci S, Delfanti S, Rovati B, Ronzoni M, Loupakis F, Brugnatelli S, Tinelli C, Villa E, Falcone A, Danova M: Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in bevacizumab-based treatment for advanced colorectal cancer. J Cancer Res Clin Oncol, 138: 1187-1196, 2012.
65. Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB: Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med, 2: 234-242, 2013.
66. Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT: Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer, 103: 1407-1414, 2010.
67. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ: Pharmacogenetic angiogenesis profiling for first-line bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res, 17: 5783-5792, 2011.
68. Kopetz S, Hoff PM, Morris JS, Wolff RA, Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, Lieu C, Yan S, Tran HT, Ellis LM, Abbruzzese JL, Heymach JV: Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. Clin Oncol, 28: 453-459, 2010.
69. Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J, Zarate R, Bandres E, Garcia-Foncillas J: Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer, 107: 287-290, 2012.
70. Hirashima Y, Yamada Y, Tateishi U, Kato K, Miyake M, Horita Y, Akiyoshi K, Takashima A, Okita N, Takahari D, Nakajima T, Hamaguchi T, Shimada Y, Shirao K: Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis. Int J Cancer, 130: 2359-2365, 2012.
71. Osawa G, Yoshimatsu K, Yokomizo H, Okayama S, Sagawa M, Naritaka Y: Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography. Cancer Chemother Pharmacol, 72: 209-215, 2013.
72. Boisen MK, Johansen JS, Dehlendorff C, Larsen JS, Osterlind K, Hansen J, Nielsen SE, Pfeiffer P, Tarpgaard LS, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Jensen BV: Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol, 24: 2554-2559, 2013.
73. Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J: Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. Oncologist, 18: 1004-1012, 2013.
74. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ: Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol, 31: 1219-1230, 2013.
75. Custodio A, Barriuso J, de Castro J, Martínez-Marín V, Moreno V, Rodríguez-Salas N, Feliu J: Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: Current evidence and future perspectives. Cancer Treat Rev, 39: 908-924, 2013.